GGrantIndex
← Search

CANCER EPIDEMIOLOGY PROGRAM

$33,078P30FY2010CANIH

Albert Einstein College Of Medicine, Bronx NY

Investigators

Linked publications, trials & patents

Paper 39499645Paper 39392861Paper 39378878Paper 39332920Paper 39259591Paper 39207105Paper 39193906Paper 39127153Paper 39081315Paper 39028768Paper 39025270Paper 38902475Paper 38898085Paper 38896451Paper 38863869Paper 38778498Paper 38753503Paper 38717519Paper 38700353Paper 38699331Paper 38679747Paper 38657656Paper 38645169Paper 38643166Paper 38608634Paper 38597673Paper 38571760Paper 38565851Paper 38559037Paper 38477945Paper 38463959Paper 38458178Paper 38436133Paper 38405931Paper 38402617Paper 38400039Paper 38387080Paper 38352476Paper 38334805Trial NCT05016622Trial NCT04514484Trial NCT04401670Trial NCT03648983Trial NCT02774291Trial NCT02649569Trial NCT02578888Trial NCT02575872Trial NCT02527304Trial NCT02507076Trial NCT02382419Trial NCT02277561Trial NCT02112552Trial NCT02073968Trial NCT02038153Trial NCT02009436Trial NCT01958580Trial NCT01939210Trial NCT01899326Trial NCT01899261Trial NCT01897454Trial NCT01897441Trial NCT01857271Trial NCT01772420Trial NCT01697293Trial NCT01695941Trial NCT01605032Trial NCT01408160Trial NCT01367301Trial NCT01351909Trial NCT01319539Trial NCT01231906Trial NCT01145430Trial NCT01142401Trial NCT01061606Trial NCT01041027Trial NCT01001910Trial NCT00950365Trial NCT00470301Trial NCT00450944Trial NCT00437034Trial NCT00392353Trial NCT00324740Trial NCT00182767Trial NCT00179348Trial NCT00121251Trial NCT00096317Trial NCT00066638Trial NCT00057863Trial NCT00055692Trial NCT00030706Trial NCT00019474Trial NCT00004864Trial NCT00004863Trial NCT00003867Trial NCT00002461Patent 9671391Patent 7709613Patent 6821725Patent 6013468Patent 5876979

Abstract

The major goal of the Cancer Epidemiology Program (CEP) is to understand the pathogenesis of human cancers at the molecular level through the use of observational and interventional studies in human populations. This effort includes a number of large prospective cohort investigations, case-control studies, population-based cross-sectional studies, and hospital-based projects, to identify etiologic risk factors and cancer biomarkers related to the multiple stages of tumorigenesis. Study populations derive from the Bronx/NYC AECC catchment area and regional/national and international inter-institutional collaborations. The scope of research has increased with faculty recruitment and expanded studies by senior CEP investigators. Substantial progress has been made in several molecular epidemiologic research areas. This includes (i) viral causes of cancer- human papillomavirus, simian virus 40, and hepatitis C virus;(ii) the epidemiology of breast cancer and its precursors;(iii) the role of host immunity including studies on immune compromised patients, immune genes (HLA and KIR), and specific immune responses to viral oncoproteins. New research initiatives include (iv) inflammation and cytokines in the development of colorectal cancer and polyps;(v) risk factors for head/neck cancer;(vi) endocrine-based cancer risk factors such as hyperinsulinemia and insulin-like growth factors (IGF), energy consumption, diabetes and obesity, sex hormones, and (vii) genetic epidemiology - studies of gene polymorphisms (e.g., in the insulin and IGF signaling pathways), variations in gene expression (involving use of mRNA arrays), and epigenetic changes (e.g., DMA methylation). Studies on HPV are being translated into therapeutic (vaccine) and screening approaches for cervical cancer. A Biostatistics Shared Resource was established with several members based in the CEP, with ongoing methodological research. There has been increased research in cancerrelated behaviors - substance abuse (e.g., cigarettes/alcohol), energy consumption/obesity, and exercise, with funded intervention efforts. There are currently 16 program members from 7 academic departments supported by 12 NCI ($2.6M Direct) and 4 other NIH grants. There are five new members. Since the last CCSG review there have been 218 research papers by program members of which 19% represent intraprogrammatic, and 7% interprogrammatic collaborative publications.

View original record on NIH RePORTER →